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1. INTRODUCTION AND OBJECTIVES 
 
 Cells exchange growth and differentiation signals through a repertoire of 
several diffusible polypeptides known generically as growth factors. Peptide growth 
factors are omnipresent molecules that coordinate every conceivable aspect of 
mammalian development, growth, physiology, and pathology. Peptide growth factors 
regulate critical cellular functions including stimulatory or inhibitory effects but also 
immune response or tumor growth. These molecules can regulate the cell function by 
autocrine, paracrine, juxtacrine or endocrine mechanisms (Sporn & Roberts 1988).  
Many peptide growth factors have been isolated and characterized, including:  
Nerve Growth Factor (NGF), Insulin-Like Growth Factors (IGF-I and II), Platelet-
Derived Growth Factors (PDGFs), Fibroblast Growth Factor (FGF), Interleukins (ILs), 
Hepatocyte Growth Factor (HGF), Transforming Growth Factor-β (TGF-β) and 
Epidermal Growth Factor (EGF) (James & Bradshaw 1984).  
The epidermal growth factor (EGF)-like peptides are emerging as major 
players in regulating different aspects of animal and human physiology and 
pathology. The EGF family includes Epidermal Growth Factor (EGF) itself, 
Transforming Growth Factor–α (TGFA), Heparin-binding Epidermal Growth Factor 
(HBEGF), Amphiregulin (AREG), Betacellulin (BTC), Epiregulin, (EREG) and Epigen 
(EPGN) (COHEN 1962; Derynck et al. 1984; Higashiyama et al. 1991; Shoyab et al. 
1988; Shing et al. 1993; Toyoda et al. 1995; Strachan et al. 2001). The members of 
the EGF family bind and activate extracellular domains of a family of receptor called 
transmembrane receptor tyrosine kinase (RTKs) (Ullrich et al. 1984; Yamamoto et al. 
1986; Kraus et al. 1989; Plowman et al. 1993; Massague & Pandiella 1993; van der 
et al. 1994). RTKs play a fundamental role in the regulation and differentiation of cell 
growth, and one of the most researched RTK’s family comprises the four receptors 
called ErbB1 (EGFR), ErbB2, ErbB3 and ErbB4 (Schlessinger & Ullrich 1992; Yarden 
& Sliwkowski 2001; Holbro & Hynes 2004). 
The EGFR and its ligands elicit essential actions in reproduction. For instance, 
different Egfr ligands have been shown to be involved in oocyte maturation and 
ovulation (Park et al. 2004; Ashkenazi et al. 2005; Shimada et al. 2006; Yoshino et 
al. 2006), preimplantational embryonic development (Hardy & Spanos 2002), and 
implantation (Das et al. 1995; Raab et al. 1996; Das et al. 1997a; Das et al. 1997b; 
Das et al. 1997c; Paria et al. 1999). 
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Btc, a rather poorly characterized Egfr ligand, was initially isolated from the 
conditioned medium of a mouse pancreatic β-cell carcinoma cell line (Shing et al. 
1993). Although, in many aspects, Btc reproduces the actions of other Egfr ligands, it 
has some unique structural and functional properties (reviewed in (Dunbar & 
Goddard 2000). Concerning reproduction, Btc was identified as one of the Egfr 
ligands expressed in the mouse uterus exclusively at the sites of blastocyst 
apposition at the time of attachment reaction (day 4) and through the early phase of 
implantation (day 5) (Das et al. 1997a). In addition, it was identified as a mediator of 
luteinizing hormone (LH) (Park et al. 2004; Ashkenazi et al. 2005; Hernandez-
Gonzalez et al. 2006) and prostaglandins (PGs) and progesterone receptor PGR) 
(Shimada et al. 2006) actions in the ovulatory follicle. Finally, Btc was recently 
identified as a possible ovarian mediator of bone morphogenetic protein 15 (BMP-15) 
actions, an oocyte-specific growth factor that plays a major role in determining 
ovulation quota in mammals (Yoshino et al. 2006). 
Although mice lacking Btc expression show no overt phenotype and appear to 
reproduce normally (Jackson et al. 2003), transgenic mice overexpressing the growth 
factor show a whole array of phenotypical alterations (Schneider et al. 2005). During 
the routine breeding of these mice in our animal facility we observed that Btc 
transgenic female and male mice, as compared with wild-type littermates, appeared 
to produce fewer pups per litter and had often non-productive matings. This 
observation led us to investigate the different stages of the reproductive process.  
 In the present investigation, we systematically studied different aspects of Btc 
transgenic female’s and male’s reproduction, including puberty initiation, ovulation, in 
vivo and in vitro oocyte maturation, sperm parameters, ovulation, in vivo and in vitro 
fertilization, and implantation in order to uncover the reason for their reduced fertility.  
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2. REVIEW OF THE LITERATURE 
 
2.1 Growth Factors 
 
Peptides with potent stimulatory or strong inhibitory effects on cell proliferation 
have been historically termed growth factors. Moreover, peptide growth factors 
regulate many other critical cellular functions that have little to do with growth itself, 
such as signal transduction, cell survival, differentiation, cell adhesion, cell migration, 
immune response, hematopoiesis, inflammation, tissue repair, atherosclerosis and 
cancer. Peptide growth factors provide an essential way for a cell to communicate 
with its immediate environment and to ensure that there is a proper local homeostatic 
balance between the numerous cells that comprise a tissue. The mechanism of local 
cellular regulation by classical endocrine molecules involves their interface with 
autocrine and paracrine mechanisms of action of peptide growth factors (Sporn & 
Roberts 1988).  
Many peptide growth factor have been isolated and characterized, including:  
Nerve Growth Factor (NGF), Insulin-Like Growth Factors (IGF-I and II), Platelet-
Derived Growth Factor (PDGF), Fibroblast Growth Factor (FGF), Interleukins (ILs),  
Hepatocyte Growth Factor (HGF), Transforming Growth Factor-β (TGF-β) and 
Epidermal Growth Factor (EGF) (James & Bradshaw 1984).  
Many growth factors derive from soluble precursors that mature through 
proteolytic cleavage within the cell. Another class of growth factors is called 
membrane-anchored growth factors and the biological effects of these growth factors 
are exerted on the cell surface by interacting with the extracellular domains of 
transmembrane receptor tyrosine kinase (RTKs) (Massague & Pandiella 1993; van 
der et al. 1994). RTKs play a fundamental role in the regulation of cell growth and 
differentiation. Ligand binding induces dimerization, activation of the intracellular 
kinase domain, and autophosphorylation by an intermolecular mechanism (COHEN 
1962; Derynck et al. 1984; Holmes et al. 1992; Shing et al. 1993; Shoyab et al. 1988; 
Toyoda et al. 1995; Schlessinger & Ullrich 1992). 
Peptide growth factor effects also depend on the stage of development or 
differentiation of its target cells. For example, the growth of fibroblasts from very early 
human embryos is stimulated by TGF-β, while the growth of fibroblasts from older 
embryos is inhibited by this peptide (Hill et al. 1986). Furthermore, it is clear that the 
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same growth factors that play a key role in the malignant process in cancer cells are 
expressed physiologically by cells that mediate inflammation and repair, namely 
platelets, macrophages, and lymphocytes (Sporn & Roberts 1986).  
  
2.1.1 The Epidermal Growth Factor Receptor and its Ligands 
 
In 1962, Cohen reported the isolation of a polypeptide from the submaxillary 
gland of male mice that accelerated eyelid opening and incisor eruption in the 
newborn animal. This polypeptide, EGF, was subsequently isolated from extracts of 
this tissue as a high molecular weight form. Its effects on the cell include 
mitogenesis, nutrient transport, glycolysis and morphological changes (COHEN 1962; 
Taylor et al. 1970). 
EGF turned out to be the founding member of a family of seven Epidermal 
Growth Factor Receptor (EGFR) ligands (Harris et al. 2003). The common structural 
domain shared by these family members is a 40–60 amino acid domain 
characterized by six cysteine residues forming three disulphide bonds (Savage, Jr. et 
al. 1973). EGF family members are transmembrane proteins that undergo proteolytic 
cleavage to release their mature form into extracellular space. Major sheddases are 
members of the ADAM (a disintegrin and metalloprotease) family (Sahin et al. 2004). 
The epidermal growth factor family includes Epidermal Growth Factor (EGF), 
Transforming Growth Factor–α (TGFA), Heparin-binding Epidermal Growth Factor 
(HBEGF), Amphiregulin (AREG), Betacellulin (BTC), Epiregulin, (EREG) and Epigen 
(EPGN) (COHEN 1962; Derynck et al. 1984; Holmes et al. 1992; Shing et al. 1993; 
Shoyab et al. 1988; Toyoda et al. 1995).  
In addition to the EGFR, these growth factors also bind and activate the 
related tyrosine kinase receptors ErbB2 (neu), ErbB3 and ErbB4 (Ullrich et al. 1984; 
Yamamoto et al. 1986; Kraus et al. 1989; Plowman et al. 1993), (Figure 2.1).  As 
typical RTKs, the ErbBs consist of an extracellular domain where ligand binding takes 
place, a short transmembrane domain and a cytoplasmic region containing the 
catalytic protein tyrosine kinase (Schlessinger 2000). Ligand binding and subsequent 
dimerization stimulates the receptor enzymatic activity, resulting in phosphorylation of 
cytoplasmatic domains. These phosphorylated residues serve as docking sites for a 
variety of signaling molecules whose recruitment initiate a cascade of intracellular 
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signaling. Subsequently, the ligand-receptor complex is internalized and degraded 
within lysosomes (Yarden & Sliwkowski 2001). 
TGFA 
(1) 
EREG
(1,4) 
AREG 
(1) 
EGF 
(1) 
BTC 
(1,4) 
HB-EGF
(1,4) 
EPGN
(1) 
1    2 1    1  2   2  4   2  1   4  3   2  4   4  3   4  3   3 1    3 
 
Figure 2.1 EGFR ligands and the ErbB network. Ligands and the ten dimeric receptor 
combinations comprise the input layer. Numbers in each ligand block indicate the 
respective high-affinity ErbB receptors. For simplicity, specificities of receptor binding 
are shown only for BTC that possess the apparently unique property of activating the 
ErbB2/3 combination. ErbB2 binds no ligand with high affinity, and ErbB3 
homodimers are catalytically inactive. 
 
2.1.2 Betacellulin 
 
Btc was initially described, purified and cloned from a mouse insulinoma cell 
line (Shing et al. 1993).  In the same year, the human BTC cDNA was identified and 
characterized (Sasada et al. 1993). Subsequently it was characterized in the bovine 
species and in the rat (Dunbar et al. 1999; Tada et al. 2000). 
The human BTC precursor (pro-BTC, Figure 2.2) encodes a 178 amino acid 
primary translation product and consists of: 
- aa 13-26, presumptive signal peptide; 
- aa 27-31, short propeptide; 
- aa 32-111, mature BTC containing the EFG motif; 
- aa 112-124, short juxtamembrane domain; 
- aa 125-138, hydrophobic transmembrane domain; 
- aa 139-178, Cytoplasmic tail domain. 
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The single copy gene for mouse Btc maps to chromosome 5 and for human 
BTC to chromosome 4q13-q21 (Harris et al. 2003; Dunbar & Goddard 2000; Pathak 
et al. 1995). The structure of genes encoding Btc and others members of EGF family 
(Tgfa, Areg, and Hbegf) are highly conserved: 
- exon 1, encodes the 5´UTR and signal peptide; 
- exon 2, encodes the N-terminal precursor; 
- exon 3, comprises the mature EGF, including the first two disulfide loops of 
the EGF motif; 
- exon 4, comprises the third loop of the EGF-like motif and the 
transmembrane domain; 
- exon 5, comprises the cytoplasmic region; 
- exon 6, encodes the 3´UTR. 
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Figure 2.2 The domain structure of the pro-Btc. 
 
The mature soluble form of mouse Btc consists of 80 amino acid residues and 
its molecular mass is 32 kDa. Btc is synthesized as a transmembrane precursor and 
its ectodomain is located in the extracellular domain. Due to this location, it is subject 
to proteolytic cleavage to produce a soluble mature growth factor (Figure 2.3). 
Reports suggest the role of metalloproteinases, MAP kinases and disintegrin in the 
processing of the ectodomain (Peschon et al. 1998; Izumi et al. 1998; Fan & Derynck 
1999; Gechtman et al. 1999). Members of the ADAM family of enzymes have been 
identified as the main EGFR ligand sheddases (Sahin et al. 2004);  (Tousseyn et al. 
 7
2006). Especially ADAM10 and ADAM17 are involved in the shedding of Egfr ligands. 
ADAM17 emerged as a constitutive sheddase of Tgfa, Areg, Hbegf, and Ereg, which 
is consistent with the essential role for ADAM17 in activation of the EGFR during 
development (Holbro & Hynes 2004). ADAM10 was found to be the major sheddase 
for Btc and Egf (Sahin et al. 2004). 
Interestingly, BTC is a pan-ErbB ligand, capable of binding to ErbB1 and 
ErbB4 homodimers and all heterodimeric combinations including ErbB2/3 (Yarden & 
Sliwkowski 2001). 
 
 
Figure 2.3 Schematic illustration of the structure of mature Btc (Dunbar & 
Goddard 2000). 
 
Btc is expressed in a wide range of tissues in the mouse, with particularly high 
levels in the liver, kidney, pancreas, small intestine and uterus (Shing et al. 1993; 
Seno et al. 1996; Kojima et al. 2003). Btc has also been shown to be expressed in 
heart, lung, colon, testis and ovary (Seno et al. 1996). Btc expression in the gastric 
surface, jejunum and colon suggests an important role also in the gastrointestinal 
tract (Kallincos et al. 2000). 
Btc is believed to play a major role in the physiology of the endocrine 
pancreas. For instance, Btc could convert pancreatic tumor cells into insulin-secreting 
cells and is required for the induction of insulin and glucokinase gene expression in 
glucagonoma cells (Mashima et al. 1996; Watada et al. 1996; Li et al. 2005). 
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Furthermore, Btc has been localized in primitive duct cells in fetal pancreas and 
some islet cell populations demonstrating a close association with insulin production 
(Tada et al. 1999). Evidence linking Btc and pancreas development was revealed by 
the administration of recombinant Btc resulting in improved glucose tolerance in mice 
with diabetes (Yamamoto et al. 2000). These findings can be associated with β-cell 
differentiation and regeneration from ductal or acinal cells. 
Reflecting its wide expression in vivo, BTC expression has been detected in a 
variety of cultured cell lines. In many cases the addition of BTC causes altered cell 
proliferation, differentiation, survival and migration. Table 2.1 provides an overview of 
the reports describing these actions. 
Btc was identified as one of the Egfr ligands expressed in the mouse uterus 
exclusively at the time of implantation (Das et al. 1997a). In addition, it was identified 
as a mediator of luteinizing hormone (LH) (Park et al. 2004; Ashkenazi et al. 2005; 
Hernandez-Gonzalez et al. 2006) prostaglandins (PGs) and progesterone receptor 
(PGR) (Shimada et al. 2006) actions in the ovulatory follicle and as a possible 
oocyte-specific growth factor (Yoshino et al. 2006). 
Mice lacking Btc are viable, fertile and show no overt phenotype (Jackson et 
al. 2003). This is believed to be a consequence of functional redundancy within the 
family of Egfr ligands. 
Transgenic mice overexpressing Btc ubiquitously exhibit a whole range of 
phenotypical alterations including high early postnatal mortality, impaired growth and 
reduced adult body weight, bone alterations, cataract and retinal problems, and 
pulmonary pathology (Schneider et al. 2005). 
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Table 2.1 Expression and effects of BTC on different cells culture lines. 
in vitro Culture BTC expression and effects Reference 
Retinal pigment 
epithelial, canine kidney 
epithelial, and vascular 
smooth muscle cells 
Stimulation of the cell proliferation Shing et al. 1993 
BALB/c 3T3 fibroblasts Stimulation of the cell proliferation Watanabe et al. 1994* 
Keratinocytes 
Transcriptionally up-regulated BTC, indicating a 
further role in the development of the neoplastic 
phenotype. 
Dlugosz et al. 1995 
Pancreatic AR42J cells Conversion of the amylase-secreting cells to insulin-secreting cells Mashima et al. 1996* 
Breast tumor cell lines 
Tyrosine phosphorylation of erB1 and erbB4; 
Growth stimulation of the mammary epithelial 
cells, 3 fold. 
Beerli &Hynes 1996 
PDX(+)αTC1.6 Induction of insulin gene expression Watada et al. 1996 
Pharyngeal carcinoma 
cells 
Up-regulation of MMP-9 and increased tumor 
cell invasion. O-Charoenrat et al. 2000a 
Pharyngeal carcinoma 
cells Expression of mRNAs and protein production O-Charoenrat et al. 2000b 
Pharyngeal carcinoma 
cells 
Up-regulation of VEGF-A and VEGF-C 
transcript levels; 
Down-regulation of VEGF-D m RNA. 
O-Charoenrat et al. 2000c 
Human aortic vascular 
smooth muscle cells Mitogenic activity Tamura et al. 2001* 
Sertoli cells Increase DNA synthesis by the Sertoli cells. Petersen et al. 2001 
Middle ear epithelium Hyperplasia of the middle ear mucosal epithelium Palacios et al. 2001 
Keratinocytes 
Involvement in epidermal morphogenesis 
and/or in maintenance of the differentiated 
phenotype of psoriatic epidermis. 
Piepkorn et al. 2003 
Seminiferous tubule Dose-dependent stimulatory effects on DNA synthesis. Wahab-Wahlgren et al. 2003
Pharyngeal carcinoma 
cells 
Induction of MMP-9 production and invasion 
primarily through activation of EGFR, MAPK 
and PI3K/Akt. 
O-Charoenrat et al. 2004 
Cumulus-oocyte 
complexes Cumulus expansion and maturation Park et al. 2004 
Cumulus-oocyte 
complexes 
Partial stimulation of the resumption of meiosis, 
activation of genes involved in cumulus 
expansion, and follicle rupture in vitro 
Ashkenazi et al. 2005 
Pancreatic ducts cells 
Proliferation (spreading and monolayer 
formation) and phosphorylation of MEK1/2 and 
ERK1/2. 
Rescan et al. 2005 
Pancreatic β-cells Differentiation and conversion of the β-cells to insulin-producing cells Ogata et al. 2005** 
Transdifferentiated β-
cells Increase insulin mRNA expression Li et al. 2005 
*Recombinant human BTC, **BTC-δ4: splice isoform of BTC lacking a transmembrane domain 
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2.2 Female Reproduction 
 
EGFR ligands have been shown to play a significant role in female 
reproductive functions in humans and animals, such as puberty onset, ovulation and 
implantation processes (Leach et al. 1999; Chobotova et al. 2002; Dey et al. 2004); 
(Hourvitz et al. 2006). Interestingly, they have also been implied in the development 
of cervical and endometrial cancer (Pfeiffer et al. 1997; Srinivasan et al. 1999).  
Female sexual maturation requires the coordinated and timely activation of 
luteinizing hormone-releasing hormone (LHRH) neurons. LHRH binds to specific 
receptors to stimulate the secretion of the gonadotropins LH and FSH and these 
hormones promote gonadal development and support reproductive physiology. One 
of these pathways uses the EGFR ligands and receptors. The functional integrity of 
both Egfr and erbB-4 signaling is critical for the time of puberty, while the suppression 
of Egfr activity during sexual differentiation in mice changes the time of puberty 
initiation (Apostolakis et al. 2000; Ojeda et al. 2003; Prevot et al. 2005).  
Oocyte maturation and ovulation require several sequential events involving a 
timed secretion of hormones that can induce expression of EGF-like growth factors. 
Areg, Ereg, and Btc can also recapitulate the oocyte maturation in vitro (Richards 
1994; Richards et al. 1995; Richards et al. 2002; Park et al. 2004). 
In humans, due to the interest in infertility studies, the expression of growth 
factors in human endometrium has been extensively investigated. EGF, TGFA, 
AREG, BTC and the ErbBs were found to be expressed with a variation during the 
menstrual cycle, with maximal levels in the late secretory phase, when the 
endometrium becomes receptive, demonstrating an association with the implantation 
process (Imai et al. 1995; Srinivasan et al. 1999; Ejskjaer et al. 2005). In mice, 
multiple EGFR ligands are expressed around the time of blastocyst implantation, 
revealing a mechanism to assure implantation (Carson et al. 2000; Das et al. 1994b; 
Das et al. 1995; Das et al. 1997a; Lim et al. 1998). 
The Table 2.2 gives an overview of the expression and actions of EGFR 
ligands in the female reproductive organs. 
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Table 2.2 Expression and actions of the EGFR-ligands in the female reproductive 
tract.  
 
EGFR-ligand Expression Effects References 
Hypothalamus Stimulation of the release of LHRH; Onset of puberty 
(Plata-Salaman 1991; Kaser et 
al. 1992; Apostolakis et al. 
2000) 
Endometrial epithelium Growth differentiation (Nelson et al. 1991) 
Trophoblast Implantation (Hofmann et al. 1992) 
Endometrial epithelium Endometrial proliferation, regulated by E2
(Huet-Hudson et al. 1990; Imai 
et al. 1995) 
EGF 
Endometrium Regulation of angiogenesis (Moller et al. 2001) 
Luminal Epithelium Uterine receptivity; Implantation (*) 
(Das et al. 1994b; Birdsall et 
al. 1996; Raab et al. 1996; 
Paria et al. 1999; Paria et al. 
2001; Lessey et al. 2002;  
Hamatani et al. 2004; Klonisch 
et al. 2001) 
Stroma und glandular 
epithelium cells 
Proliferation of stromal cells; 
Decidualization 
(Chobotova et al. 2002; 
Chobotova et al. 2005) 
Deciduum and extravillous 
trophoblast Implantation and trophoblast invasion (Leach et al. 1999) 
HBEGF 
Ovary Mitogen for granulosa cells; maturation of the follicles (Pan et al. 2004) 
Hypothalamus Onset of puberty (Ma et al. 1994) 
Luminal epithelium and 
peripheral stromal cells Implantation (Das et al. 1997b) 
Luminal, glandular and 
stromal cells 
embryonic development, preparation 
of the uterus for implantation, and 
decidualization 
(Tamada et al. 1991) 
Epithelial lining in human 
endometrium Growth of endometrium (Ejskjaer et al. 2005) 
TGFA 
Endometrial epithelium Endometrial proliferation, regulated by E2
(Imai et al. 1995) 
Preovulatory follicles Meiosis and Cumulus expansion (Park et al. 2004) 
Luminal epithelium Uterine receptivity, regulated by P4 (Das et al. 1995; Das et al. 1997b) 
AREG 
Leucocytes and stromal 
cells in human 
endometrium 
Growth of endometrium (Ejskjaer et al. 2005) 
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Preovulatory follicles Meiosis and Cumulus expansion (Park et al. 2004) 
Luminal epithelium and 
underlying stroma Implantation (*) 
(Das et al. 1997a; Paria et al. 
2000) 
Placenta Placental growth 
(Maruo et al. 1995; Birdsall et 
al. 1996; Watanabe et al. 
1994) 
Epithelial lining in human 
endometrium Growth of endometrium (Ejskjaer et al. 2005) 
 
BTC 
Ovary Involvement in ovulatory process 
(Hourvitz et al. 2006; Yoshino 
et al. 2006; Woods & Johnson 
2006) 
Preovulatory follicles Meiosis and cumulus expansion (Park et al. 2004) 
Luminal epithelium and 
Stroma Implantation (*) (Das et al. 1997a) 
Stromal cells in human 
endometrium Growth of endometrium (Ejskjaer et al. 2005) 
Placenta Maintenance/development of normal cell growth (Toyoda et al. 1997) 
EREG 
Ovary Involvement in ovulatory process (Hourvitz et al. 2006) 
 
(*) proposed 
 
 
 
2.2.1 Sexual maturity 
 
The initiation of mammalian puberty requires the activation of hypothalamic 
neurons secreting the neuropeptide LHRH. LHRH stimulates the secretion of pituitary 
gonadotropins. Astrocytes affect LHRH neuronal function via cell-cell signaling 
mechanisms involving several growth factors acting via receptors with tyrosine kinase 
activity (Ojeda et al. 2000). Egf and Tgfa and their receptors are key players in the 
glial-neuronal interactive process that regulates LHRH secretion. Tgfa and 
Neuregulin (NRG) are produced in hypothalamic astrocytes and stimulate LHRH 
release indirectly via activation of their respective receptors, located on astrocytes. 
Activation of Egfr by Tgfa, and/or the erbB2/erbB4 receptor complex by Nrg, leads to 
E2, which then acts directly on LHRH neurons to stimulate LHRH release. A central 
blockade of Tgfa or Nrg action delays puberty, and focal overexpression of Tgfa 
advances it (Ojeda & Ma 1998). 
The increase in pulsatile release of gonadotropin releasing hormone (GnRH) 
is very important in the puberty. Glial cells facilitate GnRH secretion via cell-cell 
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signaling loops mainly initiated by members of the EGF family. The control of these 
mechanism may involve the transcriptional regulation of subordinate genes that, by 
contributing to neuroendocrine maturation, are required for the initiation of the 
pubertal process (Ojeda et al. 2003). 
Transgenic mice expressing a dominant-negative erbB4 receptor (DN–erbB4) 
were created to evaluate the function of the astrocytic ErbB receptors in the timely 
advent of puberty. The transgenic mice exhibit delayed sexual maturation and a 
diminished reproductive capacity in early adulthood. These abnormalities are related 
to a deficiency in pituitary gonadotropin hormone secretion, caused by impaired 
release of LHRH. Mice carrying both the Wa-2 mutation (a defective Egfr) and a DN-
erbB-4 mutant receptor exhibit a more pronounced delay in the onset of puberty and 
a dramatically impaired adult reproductive function in comparison to single-mutant 
mice and wild-type animals. These defects appear to be caused by loss of ErbB 
receptor-mediated astrocyte-to-neuron communication (Prevot et al. 2003; Prevot et 
al. 2005). 
Tgfa is widely distributed in the nervous system, both glial and neuronal cells 
contributing to its synthesis, and have a neuronal participation in the control of female 
puberty. Tgfa contributes to the acceleration of puberty induced by anterior 
hypothalamic lesions. They also indicate that activation of Tgfa gene expression in 
glial cells is a component of the hypothalamic response to injury (Junier et al. 1991; 
Junier 2000). 
Increased circulating levels of growth factors precede intracerebral 
aromatization of androgens to estrogen (E) during sexual differentiation and 
development (MacLusky & Naftolin 1981) and changes in E at the time of initiation of 
puberty (Ma et al. 1992). Indeed, the initiation of the puberty in females is dependent, 
in part, on activation of hypothalamic membrane-bound growth factor receptors (Ma 
et al. 1994). The absence of Egfr activity in mice delays the initiation of puberty and 
estrus cyclicity and the synchronization of mating behavior and estrous is disrupted. 
These findings demonstrate a greater role for growth factors in the adult brain. Rats 
and mice in the absence of E exhibit reproductive behavior 1 h after 
intracerebroventricular (icv) injection of Egf, Areg and Tgfa, demonstrating that 
growth factors can signal through the classical estrogen receptor (ERα) to alter in 
vivo function in rodent reproduction (Apostolakis et al. 2000). 
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In summary, while a central role for Egfr, ErbB4, Tgfa and Egf in the onset of 
female puberty and sexual maturity has been clearly demonstrated, no information is 
available about the role of Btc in this process. 
 
2.2.2. Oocyte maturation and ovulation 
 
Ovulation, initiated by the proestrus LH surge consists of several sequential 
follicular events involving enlargement of the antrum, expansion of the follicle and 
ovarian wall at the apex of the mature follicles and release of the fertilizable oocyte. 
This process involves a highly synchronized and exquisitely timed cascade of gene 
expression (Richards 1994, Richards et al. 1995, Richards et al. 2002). The LH 
analog hCG induces the transient and sequential expression of the EGF family 
members Areg, Ereg and Btc. An ovulatory dose of LH was shown to induce a rapid 
and transient expression of Btc mRNAs 1-3 h after the injection (Ashkenazi et al. 
2005). The presence of EGF-like activity in follicular fluid (Hsu et al. 1987) supports 
this concept. Incubation of follicles with Areg, Ereg, and Btc recapitulates the 
morphological and biochemical events triggered by LH, including cumulus expansion 
and oocyte maturation (Park et al. 2004). Thus, these EGF-related growth factors are 
paracrine mediators that propagate the LH signal throughout the follicle. 
A recently proposed model suggests that EGF family ligands, produced in a 
paracrine (Tgfa) or autocrine (Btc) fashion, bind with ErbB1 and/or ErbB4 receptors 
to activate Erk signaling that promotes enhanced expression of FSHR to initiate the 
process of granulosa cell differentiation subsequent to preovulatory follicle selection 
(Woods & Johnson 2006).  
Btc and Ereg were shown to be expressed in an ovulation-dependent manner 
after an analysis of mouse preovulatory and postovulatory ovarian cDNA. (Hourvitz et 
al. 2006). In this interesting study, 43 of 98 cDNA clones showed a true ovulation-
selective/specific expression pattern. Btc was also recently identified as a possible 
ovarian mediator of bone morphogenetic protein 15 (BMP-15) actions, an oocyte-
specific growth factor that plays a major role in determining ovulation quota in 
mammals (Yoshino et al. 2006). 
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2.2.3 Implantation  
 
In the mouse, the process of implantation can be classified into three stages: 
apposition, adhesion, and penetration. Apposition is the stage when embryonic 
trophectoderm cells become closely apposed to the uterine luminal epithelium. This 
is followed by the adhesion stage in which the association of the trophectoderm and 
the luminal epithelium is sufficiently intimate as to resist dislocation of the blastocyst 
by flushing the uterine lumen. The stage of penetration involves the invasion of the 
luminal epithelium by the trophectoderm. Stromal cell differentiation into decidual 
cells (decidualization) is more extensive, and the loss of the luminal epithelium is 
evident at this stage. These three stages of implantation form a continuum (Enders & 
Schlafke 1969; Schlafke & Enders 1975; Enders & Lopata 1999). 
The attachment reaction coincides with a localized increase in stromal 
vascular permeability at the site of the blastocyst. This can be demonstrated by 
intravenous injection of a macromolecular blue dye resulting in discrete blue bands 
along the uterus (uterine blue reaction). Molecular signals coordinate the uterus 
receptivity and the interactions between the embryo and the uterus to initiate the 
process of implantation (Psychoyos 1973; Paria et al. 1993b; Lee & DeMayo 2004). 
In mammals, the uterus differentiates into an altered state when blastocysts 
are capable of effective two-way communication to initiate the process of 
implantation. This state is termed uterine receptivity for implantation and lasts for a 
limited period, called window of implantation. At this stage, the uterine environment is 
able to support blastocyst growth, attachment, and the subsequent events of 
implantation (Paria et al. 1993b). The establishment of the receptive uterus to support 
embryo development and implantation is primarily coordinated by ovarian hormones, 
which modulate uterine events in a spatiotemporal manner. Estrogen and 
progesterone prime the uterus for implantation (Cross et al. 1994). In the mouse the 
attachment reaction occurs in the evening (22:00-24:00) of day 4 of pregnancy (Das 
et al. 1994b).  
The expression of several growth factors, cytokines, and their receptors in the 
uterus in a temporal and cell-specific manner during the peri-implantation period 
suggests that these factors are important for implantation and that some of the 
effects of ovarian steroids in the implantation process are mediated by 
paracrine/juxtacrine effects of these growth factors (Paria et al. 1993b; Das et al. 
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1994b; Das et al. 1995; Carson et al. 2000; Paria et al. 2002; Lim et al. 2002; Norwitz 
et al. 2001). 
The blastocyst and uterus generate various factors during implantation, but it 
is likely that the molecular "cross-talk" between them involves many more yet 
unknown factors. Indeed, it is more realistic to view the process of implantation as a 
condition of equilibrium in the up-regulation and down-regulation of a diverse set of 
genes. Identification of other essential regulatory steps is necessary to further 
understand the biologic basis for the establishment of pregnancy or the underlying 
causes of pregnancy failures. Many genes that are known to be associated with the 
implantation process fall into categories similar to the genes detected with increased 
expression at the implantation site, including growth factors/cytokines and their 
receptors, transcription factors, genes encoding structural proteins, or genes 
associated with cell proliferation. Genes with increased expression at the 
interimplantation site may act to guide the blastocyst to specific sites for implantation 
or be important for embryo spacing. 81 genes were reported with differential 
expression at the implantation site during both natural and induced implantation, 
suggesting their importance for implantation and some were members of the EGF 
family of growth factors that becomes intensely localized to the uterine luminal 
epithelium surrounding the blastocyst at the onset of implantation (Reese et al. 2001).  
 
2.2.3.1 Role of EGFR family members in implantation 
 
The expression of epidermal growth factor EGF-related ligands in the mouse 
uterus (Huet-Hudson et al. 1990; Tamada et al. 1991; Das et al. 1994b; Das et al. 
1997a; Lim et al. 1998) and the Egfr and Erb-4 in the embryo (Paria & Dey 1990; 
Paria et al. 1993a; Wiley et al. 1992; Paria et al. 1999) suggests roles for these 
growth factors in embryo-uterine interactions during implantation. The expression of 
multiple receptors and ligands of the EGF family might be a protective mechanism to 
ensure the embryo development and implantation (Paria et al. 2000).  
Hbegf gene is expressed in the mouse uterine luminal epithelium surrounding 
the blastocyst 6-7 hours before the attachment reaction that occurs at 22:00-23:00 
hours on day 4 of pregnancy. In vitro studies showed that Hbegf induced blastocyst 
Egfr autophosphorylation, and promoted blastocyst growth, zona-hatching and 
trophoblast outgrowth. These results suggest possible interactions between the 
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uterine Hbegf and blastocyst Egfr very early in the process of implantation, earlier 
than any other embryo-uterine interactions defined to date at the molecular level (Das 
et al. 1994b). 
Areg mRNA levels display a transient surge throughout the uterine epithelium 
on day 4 of pregnancy. With the onset of blastocyst attachment late on day 4, Areg 
mRNA accumulated in the luminal epithelium exclusively at the sites of blastocysts 
(Das et al. 1995).  
The cell-specific “window” of expression of Btc and Ereg in the peri-
implantation mouse uterus was also examined and it was demonstrated that both 
growth factors are expressed in the uterus exclusively at the sites of blastocyst 
apposition at the time of attachment reaction and during the initial phase of 
implantation. The distribution of Btc mRNAs in the peri-implantation uterus was 
examined by in situ hybridization on days 1-8 of pregnancy. Btc is present in the 
luminal epithelium and underlying the stroma at the site of blastocyst apposition at 
23:00 on day 4 and on the morning of day 5 distinct autoradiographic signals was 
observed in an increased number of luminal epithelial and stromal cells. The 
expression of the Ereg gene was mostly similar to that of Btc, and both Btc and Ereg 
expression was not detected in implanting blastocysts (Das et al. 1997a). 
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Figure 2.4 A schematic diagram showing the expression of EGFR ligands in the periimplantation 
mouse uterus (days 1-8 pregnancy; M = morning; A = afternoon; N= night). Adapted from Das et 
al. (Dev. Biol. 190, 178-190, 1997). 
 
 Interestingly, the inappropriate expression of a transgenic human TGFA in the 
uterus delays the initiation of the implantation process, which was associated with 
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downregulation of the TGF-β receptor subtypes and deferral of uterine AREG 
expression (Das et al. 1997b). 
The implantation depends not only on maternal events, but also on the 
blastocyst itself. Transgenic mice with null allele Egfr did not cause a blockage in the 
blastocyst formation, although the inner cell mass were degenerated in the peri-
implantation period causing an embryonic death (Threadgill et al. 1995). This effect 
however, depends on the genetic background of the mouse strain. 
The Egfr (erbB1) has been examined in several aspects during the peri-
implantation period. ErbB1 was detected in the stroma, deciduum, and myometrium, 
but not in the luminal or glandular epithelium. These observations are supportive of 
the concept of paracrine or juxtacrine interactions between EGF-related growth factor 
ligands of luminal epithelial origin and blastocyst Egfr in the process of implantation 
(Das et al. 1994a). 
A model has been established that shows cooperative interaction among 
preimplantation embryos and the role of growth factors on their development and 
growth. The embryos cultured with the addition of Egf or Tgfa have their development 
improved. Detection of Egf receptors on the embryonic cell surface at eight-
cell/morula and blastocyst stages suggests beneficial effects of Egf on 
preimplantation embryo development and blastocyst functions. In the blastocyst, the 
binding was limited to trophectoderm. This study presents clear evidence that specific 
growth factors of embryonic and/or reproductive tract origin participate in 
preimplantation embryo development and blastocyst functions in an 
autocrine/paracrine manner. The mechanisms by which mitogenic and differentiating 
effects of EGF on preimplantation embryos are mediated are still unclear (Paria & 
Dey 1990). 
The spatiotemporal uteroplacental expression pattern of the four ErbB 
receptors and their ligands was studied in the rabbit. The results provide evidence for 
the functional involvement of the Egf ligand-receptor system in embryo/feto-maternal 
cross-talk during the peri-implantation. Differential expression of Egfr-ErbB4 was 
observed in the trophoblast during implantation. Marked expression of ErbB1 mRNA 
and protein were observed in the cytotrophoblast of the embryonic trophectoderm, 
with the syncytiotrophoblast layer displaying weaker staining (Klonisch et al. 2001). 
In vitro studies with human endometrial stromal cells had demonstrated that 
HBEGF has a function in endometrial maturation in mediating decidualization and 
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attenuating TNFA and TGF-β-induced apoptosis of endometrial stromal cells 
(Chobotova et al. 2005). 
Placental growth is regulated by endocrine and local growth factors (Maruo et 
al. 1991) but little information is available regarding the expression of BTC in the 
placenta and uterus (Shing et al. 1993; Watanabe et al. 1994) and (Birdsall et al. 
1996). A study was conducted to clarify the expression of Btc and its receptors, ErbB-
1 and ErbB-4, in the trophoblasts in the human placenta over the course of 
pregnancy (4th to 5th, 6th to 12th, 18th to 21st, and 38th to 40th week 
placentas(Maruo et al. 1995). BTC from very early placentas until mid placentas was 
immunolocalized in syncytiotrophoblasts, and was most abundant in early placentas. 
The levels of BTC mRNA expression in early and mid placentas were significantly 
higher than those in term placentas. The levels of erbB-1 mRNA in the early and mid 
placentas were significantly higher than those in term placentas, whereas the levels 
of erbB-4 mRNA in early placentas were significantly lower than those in mid and 
term placentas, that shows evidence for changes in expression and cytological 
localization of BTC and its receptors in the trophoblasts in human placenta over the 
course of pregnancy. BTC may play a pivotal role as a local growth factor in 
promoting the differentiated villous trophoblastic function via ErbB-1 in early 
placentas and in contributing to placental growth through the maintenance of extra-
villous trophoblast cell function via ErbB-4 in term placentas (Maruo et al. 1995).  
 
 
2.3 Male reproduction  
 
In sharp contrast to the abundant data supporting an important role for the 
EGFR ligands in the female reproductive tract, only little information is available 
about their function in the male reproductive organs. 
EGF was measured in the seminal plasma of human patients attending an 
infertility clinic. No correlation was found between EGF concentration (~ 40 ng/ml) 
and age of donor, sperm count, sperm motility, sperm morphology or period of sexual 
abstinence before sample collection. There was no significant variation in mean EGF 
levels between fertile and infertile men, suggesting that this peptide plays no role in 
the density or motility of sperm associated with fertility (Elson et al. 1984; Hirata et al. 
1987; Richards et al. 1988).  
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The circulating Egf appears to play a role in mouse spermatogenesis since the 
removal of the submandibular glands decreased the amount of circulating Egf to an 
undetectable level and caused a marked decrease in the number of mature sperm 
and spermatids (55 and 50%, respectively) and the number of spermatocytes 
increased 20%. Replacement of Egf to sialoadenectomized mice reversed completely 
both the sperm content of the epididymis and the number of spermatids in the testis 
to normal showing that Egf may play a role in the meiotic phase of spermatogenesis 
and may cause some cases of infertility like unexplained oligospermia (Tsutsumi et 
al. 1986). Interestingly, infertile men had mean blood plasma EGF concentrations 
lower than that of the fertile group. There were also statistically significant differences 
between the fertile and infertile men in sperm count, sperm viability, mean forward 
progression, testosterone, LH and FSH (Adekunle et al. 2000).  
Transgenic male mice overexpressing Egf show only few post-meiosis II 
gametes, are sterile and have reduced serum testosterone (Wong et al. 2000). This 
is in contrast to transgenic mice overexpressing Tgfa in the testis. These transgenic 
animals had no abnormal testicular morphology or alterations in spermatogenesis 
(Mullaney & Skinner 1992). Observations demonstrate that gene expression of Tgfa 
and its receptor is high during early pubertal stages when somatic cell growth is 
predominant and low at late pubertal stages when somatic cell proliferation is 
reduced. Tgfa can act as an autocrine/paracrine mitogen for the mesenchymal-
derived peritubular cell, while actions on the Sertoli cell population are not evident 
(Mullaney & Skinner 1992). Although Egf seems to be the major physiological ligand 
in germ cell development, mice with either single or triple null mutations in Egf, Tgfa, 
and Areg did not display reduced fertility (Luetteke et al. 1999). DNA synthesis in rat 
testis seminiferous tubules in vitro was stimulated with the addition of Egf, Tgfa and 
Btc. RT-PCR analysis revealed that EGFR, erbB2, erbB3 and erbB4 were all 
expressed at every stage of the spermatogenic wave, whereas differential expression 
was found in isolated Leydig, Sertoli and peritubular cells. These results show that 
EGFR-ligands are spermatogonial growth factors in vitro, suggesting a paracrine 
control of spermatogenesis in vivo (Yan et al. 1998; Wahab-Wahlgren et al. 2003).  
Expression of the EGF-like ligands EGF, TGFA, AREG, BTC, HBEGF and all 
four ErbB receptors was detected in the human and mouse prostate showing an 
evidence that ErbB signaling contributes to mouse prostate function (Adam et al. 
1999; Zhu & Jones 2004). Finally, aberrant ErbB family signaling contributes to the 
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development and metastatic progression of human prostate cancer (Klapper et al. 
2000). 
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3 ANIMALS, MATERIALS AND METHODS 
 
 
3.1 Animal Breeding  
 
All animals were maintained under non-barrier conditions in the facilities of the 
Gene Center at 22°C, 65% humidity, and a 12 h light cycle and received standard 
food and water ad libitum. Mice used in expression studies and for phenotype 
analysis were weaned at an age of three weeks, marked by ear piercing and housed 
in cages separated by sex. At the time of weaning, tail tips were clipped and frozen 
on dry ice and stored at -80°C for genotype analysis. The generation of the 
transgenic mice used in this study was described previously (Schneider et al. 2005). 
 
 
3.2 Mouse genotyping 
 
 
Proteinase K digests of mouse tail tips 
 
Reagents: 
 
EDTA Ethylene diamine tetraacetic acid, 0.5 M, ph 8.0 
Proteinase K Solution 20 mg/ml dissolved in bidistilled H2O 
Isopropanol 100% 
Ethanol 70% 
 
 
Wizard ® Genomic DNA Purification Kit (Promega) containing: 
Nuclei Lysis Solution 
RNase Solution 
Protein Precipitation Solution 
DNA Rehydration Solution 
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Assay: 
 
Each tail tip was incubated in a 1.5 ml tube with 600 µl of a solution containing 
120 ml EDTA, 500 µl Nuclei Lysis Solution and 17.5 µl Proteinase K stock solution 
overnight at 56° C and with shaking.  The next step was the addition of 3 µl of RNase 
Solution. The samples were mixed by inverting 25 times and incubated for 20 min at 
37°C. After cooling down to room temperature, 200 µl of Protein Precipitation 
Solution was added to each sample. The samples were vortexed at high speed for 20 
seconds, chilled on ice for 5 minutes and then centrifuged at 13,000 g x for 4 min. 
The supernatant was transferred into a clean tube containing 600 µl isopropanol. The 
DNA became visible as a small white pellet by gentle shaking and was centrifuged at 
13,000 x g for 2 min. After removing the supernatant, 600 µl of 70% ethanol were 
added to wash the DNA and the tubes were inverted several times. A last 
centrifugation was made under the same conditions as above, the ethanol was 
removed and the pellet was air-dried for 10 min. 50 µl of Rehydration Solution were 
added and the DNA were rehydrated by incubating at 65°C  for one hour. 
 
 
Principle of the Polymerase Chain Reaction (PCR) 
 
PCR is an in vitro method that allows up to a billion folds amplification of a 
selected DNA sequence. The reaction uses two oligonucleotide primers that 
hybridize two opposite strands and flank the target DNA sequence that is to be 
amplified. In the presence of deoxyribonucleoside triphosphates (dNTPs), a heat-
stable DNA polymerase catalyzes the elongation of the primers. A repetitive series of 
cycles involving template denaturation, primer annealing, and extension of annealed 
primers by the polymerase results In exponential accumulation of the specific DNA 
fragment. Because the primer extension product synthesized in a given cycle can 
serve as a template in the next cycle, the number of target DNA copies increases 
exponentially corresponding to each cycle. 
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PCR protocol for detecting the BTC transgen sequence 
 
 Reagents: 
 
Taq DNA polymerase Kit (Qiagen) containing: 
PCR Buffer, 10x trisCl, KCl, (NH4)2SO4, 15mM MgCl2, pH 8.7 (20°C) 
Q-Solution 5x concentrated 
MgCl2 25Mm 
Taq Polymerase 5U/µl, recombinant 94-kDa DNA polymerase, isolated 
from Thermus aquaticus, cloned in E. coli 
dNTPs Set 100 Mm aqueous solutions of dATP, dCTP, dGTP and 
dTTP, each in a separated vial 
 
Ethidium Bromide 0,1% solution in bidistilled H2O 
50x TAE running buffer 242 g Tris 
 57,1 ml Glacial Acetic Acid 
 100 ml EDTA, 0.5 M, ph 8.0 
 Ad 1 l bidistilled H2O 
6x Loading Dye 30% Glycerol 
 Bromophenol Blue 
 
To confirm the integrity of the DNA, a sequence of the β-actin gene was 
amplified using the following primers: 
 
β-actin sense 5’-GGC ATC GTC ATG GAC TCC -3’ 
β-actin  antisense 5’-GTC GGA AGG TGG ACA GGG -3’ 
 
For detection of the construct integration, following primers were use: 
 
pTORUseq  5’-CTA CAG CTC CTG GGC AAC GTG-3’ 
globpA  5’- AGA TCT CAG TGG TAT TTG TGA GCC 3’ 
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Assay procedure: 
 
The 20 µl reaction was prepared in 100 µl PCR tubes on ice, containing:  
DNA template (about 50 ng/µl) 2 µl 
Sense primer (2 µM) 1 µl 
Antisense primer (2 µM) 1 µl 
dNTPs Mix (1 mM) 2 µl 
PCR Buffer, 10x 2 µl 
Q-Solution 4 µl 
MgCl2 (25Mm) 1.25 µl 
Taq Polymerase, 5U/µl 0.1 µl 
Bidistilled H2O 6.65µl 
  
 The amplification took place in a Biometra Uno Thermocycler and was 
performed as follows: 
  
1st step: denaturation 94°C for 4 min 
2nd step: denaturation 94°C for 1 min 
3rd step: annealing 60°C for 1 min 
4th step: extension 72°C for 2 min 
5th step: extension 72°C for 10 min 
6th step: cooling 4°C 
 
Steps 2 to 4 were repeated 35 times before progression to steps 5 and 6 (36 
cycles). PCR products were mixed with 6x loading buffer, separated in 2% agarose 
TAE gels with ethidium bromide and visualized under UV light. 
 
3.3 Analysis of Body and Organ Weights 
 
Body, ovary and uterus weight of control and transgenic females at the age of 
2 months were recorded with a scale (BP221S, Sartorius, Germany). Body weight 
was measured to the nearest 0.1 g and ovary and uterus to the nearest mg.  
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3.4 Fertility Analyses 
 
Most of the routine mouse breeding for expanding the Btc transgenic lines 
involved mating of transgenic males to control females. A retrospective analysis 
shows that the number of successful matings (77/157, 49%) and pups per litter 
(8.2±0.2) was significantly reduced as compared to non-transgenic age-matched 
males (11/11, 100% successful matings and 9.9±0.4 pups per litter). A few matings 
involving transgenic females paired to control males were performed sporadically and 
these matings also revealed a clear impairment in the reproductive performance of 
transgenic females: the number of successful matings (8/13, 61.5%) and pups per 
litter (5.7±0.8) was significantly reduced. Thus, we decided to initiate extensive 
experiments to systematically analyze the reproductive fitness of transgenic females. 
In order to analyze their breeding performance, Btc transgenic mice (lines 2 
and 4) and control mice were paired with wild-type mice of the opposite sex. The 
mating pairs were: 
- WT ♀ x WT♂, n=3 
- Line 2 BTC ♀ x WT ♂, n=5 
- Line 4 BTC ♀ x WT ♂, n=5 
- WT ♀ x Line 2 BTC ♂, n=4 
- WT ♀ x Line 4 BTC ♂, n=5 
All animals were 2 months old at the beginning of the experiment. Each mating 
pair was housed together exactly three months and the litters were removed at the 
age of 4 weeks. The litter size of each mating pair was averaged. The interval to the 
first litter and litter size development were recorded.  
 
3.5 Evaluation of female puberty onset and estrous cycle tracking 
 
Wild-type (n=3) and Btc transgenic (n=4) mice were observed daily from the 
time of weaning at 21 days for the appearance of a vaginal opening (the loss of the 
vaginal closure membrane at puberty). Once this occurred, daily histological analysis 
of vaginal smears was made. Estrous cycles were monitored during three 
consecutives cycles. The cycle’s length was defined as the interval between 
proestrus smears and the onset of estrous cyclicity was defined as the first day of the 
first cycle less than or equal to 6 days in length (Nelson et al. 1990).  
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3.6 Embryo Implantation Studies 
 
Wild-type (n=6) and Btc transgenic (n=11) mice were mated with fertile males 
and used to examine the attachment reaction and progression of the implantation 
process. By the end of the day 4 or day 5 of pregnancy they were injected 
intravenously (200 µl/mouse) with a solution of Evans Blue dye (1% in PBS). Mice 
were killed 5 min after injection and blue bands along the uterus indicated the sites of 
blastocyst apposition (Das et al. 1994b). After the observation of the implantation 
sites the uterus were flushed to recover embryos that did not implant.  
 
 
3.7 Ovulation and Fertilization Analysis 
 
Female mice at 2 to 6 months of age were used for these experiments. 
Ovulation assays were performed with wild-type (n=15) and Btc transgenic (n=8) 
mice. Female were mated with wild-type vasectomized males. The females were 
examined every morning and evening for the presence of a copulatory plug 
(positive=day 0). The oviducts and ovaries were excised from mice and were placed 
into dishes containing medium (M2 supplemented with BSA). The cumulus-oocyte 
complexes (CCOs) were recovered by dissection of both ampullas on day 0.5. The 
number of ovulated oocytes was determined after enzymatic disassociation with 0.3 
% hyluronidase from the surrounding cumulus. Fertilization assays were performed 
with wild-type (n=12) and Btc transgenic (n=7) female mice which were 2 to 6 months 
old. The females were mated with wild-type males with proved fertility. The 
methodology to detect copulatory plugs and the COCs collection was the same as 
described for determination of the ovulation rate. The fertilized oocytes (zygotes) 
were counted. 
 
3.8 Cumulus-Oocyte Complex Isolation and Culture 
 
Female mice, 2 to 6 months old, were induced to superovulate with pregnant 
mare serum gonadotropin (PMSG, Intergonan) and sacrificed 48 h later to obtain the 
immature oocytes. The ovaries were removed and stored in Opti-MEM medium 
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(Gibco, Grand Island, NY) with 10% fetal calf serum (FCS; Biochrom AG). Large 
antral follicles were punctured with 28 in. × 0.5 in. 18G syringe needles to release 
COCs. Only COCs that consisted of an oocyte surrounded by at least three complete 
layers of cumulus cells were selected for further culture. COCs were taken through 
three washes of Opti-MEM medium plus 10 IU/ml PMSG and 10% FCS before being 
cultured in groups of 20 in 80µl drops of preequilibrated medium and overlaid with 
silicone oil (Sigma) in an atmosphere of 5% CO2 in air at 37°C. These oocytes were 
cultured for 16 h. At the end of the culture period, COCs were removed from the drop 
and the oocyte denuded of cumulus cells by repeated gentle pipetting in medium 
containing 0.1% hyaluronidase (Sigma). Morphological changes of the cultured 
oocytes were evaluated and classified. Immature oocytes were classified as GV 
when the germinal vesicle (GV) was present, as metaphase I (MI) when GV was 
broken down, as metaphase II (MII) when the first polar body was extruded, and as 
degenerated when oocytes were dark, granulated, or fragmented. The degree of 
cumulus expansion was assessed according to a subjective scoring system, a scale 
of 0 (no expansion) to +4 (maximal expansion) (Yoshino et al. 2006). 
 
3.9 Sperm isolation and in vitro fertilization 
 
Sperm were collected from the cauda epididymis and vasa deferentia of fertile 
mice in IVF medium (Vitrolife). The percentages of motile and progressive 
spermatozoa and the sperm concentration were recorded. The oocytes were washed 
three times in the fertilization medium (IVF, Vitrolife) and placed in fertilization drops, 
where the spermatozoa were added with a concentration of 1 x 106/ml. Six hours 
after fertilization, oocytes were denuded from the remaining cumulus cells by 
repeated gentle pipetting. We evaluated and classified the morphological changes of 
the zygotes, as appearance of two pronuclei and after 24 hours the cleavage. 
 
3.10 Sperm Analysis  
 
Sperm analyses were performed with wild-type (n=7) and Btc transgenic 
(n=11) males mice ranging from 3 to 5 months of age. After retro-orbital puncture for 
blood collection under ether anesthesia, the animals were killed by cervical 
dislocation. The two caudae epididymides and vasa deferentia were dissected and 
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placed into 0.9% NaCl in a 4-well dish (on ice). Under a microscope all remaining fat 
and visible blood vessels were removed with scissor. The epididymis was cut several 
times and the spermatozoa were left to swim out for 3-5 minutes at 37°C. The 
suspension was shacked carefully until the solution was homogenous. The sperm 
quality is checked using a computerized semen analysis system (IVOS, v 12.2, 
Hamilton Thorn Research, Beverly, MA). The percentage of motile and progressive 
sperm and concentration of sperm were recorded. We thank Dr. Auke Boersma 
(GSF) for the sperm analysis. 
 
3.11 Histological and Immunohistochemical studies 
 
Excised ovarian and uterus tissues were fixed in 4% paraformaldehyde, 
routinely processed for paraffin embedding, and serially sectioned at a thickness of 5 
µm. The sections were stained with hematoxylin and eosin and examined by light 
microscopy. Sections were deparaffinized and hydrated in PBS for 20 min. Blocking 
of endogenous peroxidase activity was achieved by incubation in 3% H2O2 in PBS for 
10 min at 37°C. The sections were incubated with the primary antibody, a goat anti-
mouse Btc antibody (R & D Systems, Wiesbaden, Germany), for 1 h at 37°C. Then, 
the sections were rewashed in TBS (Tris-buffered saline) two times for 5 min and 
incubated with the secondary antibody, a biotinylated rabbit anti-goat Ig (Dako, 
Denmark). After immunostaining, sections were stained lightly with diaminobenzidine 
(DAB), mounted, and examined under a brightfield microscope. Red deposits 
indicated the sites of immunoreactive protein. IHC was kindly performed by Maik 
Dahlhoff and evaluated by Prof. Dr. Sinowatz (Institute of Veterinary Anatomy). 
 
3.12 Statistical analysis 
 
Data are expressed as the mean ± SEM. Statistical analysis was performed 
using paired or unpaired Student’s t tests to detect significant differences between 
transgenic and control mice. Values of p<0.05 were considered significant. 
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4 RESULTS 
 
 
4.1 Analysis of Body and Organs Weight 
 
 
 
To detect a possible effect of the Btc overexpression on the weight of uterus 
and ovaries, the weight of these organs in females at 2 months of age was recorded. 
Table 4.1 shows that in comparison with wild-type females, Btc transgenic females 
exhibited a lower body weight. The absolute weight of ovary and uterus did not differ 
significantly between the two genotypes. While the same was true for the relative 
weight of the uterus, an increase in the relative weight of the ovary in transgenic 
females was detected. 
 
Table 4.1 Body weight and absolute and relative weights of the ovary and uterus of 
non-transgenic (wt) and Btc-transgenic (tg) females at the age of 2 months. The table 
shows the calculated mean values (standard deviation values are shown in brackets). 
A t-test was used to show the absence (-) or presence (*: P<0.05) of a statistically 
significant difference (∆) between groups. 
 
 Weight  % Body weight  
 wt tg ∆ wt tg ∆ 
Body (g) 22.86 (2.9) 19.67 (2.6) *    
Uterus (mg) 78.1 (34) 81.6 (21) - 0.35 (17) 0.42 (0.11) - 
Ovary (mg) 10.1 (3.9) 11.5 (2.8) - 0.04 (0.01) 0,06 (0.01) * 
n 10 11     
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4.2 Fertility measurements 
 
 
4.2.1 Males 
 
To study systematically the consequences of transgene expression on male 
and female fertility, Btc transgenic mice from Lines 2 and 4 were mated with wild-type 
animals.  
In average, control litters consisted of 9.9 ± 0.3 pups, while L2 Btc and L4 Btc 
transgenic males produced an average litter size of 7.9 ± 0.8; and 8.0 ± 0.8 pups, 
respectively (p<0.05). The interval to the first litter was not significantly different 
between groups (Table 4.2). 
 
Table 4.2 Mean values (± SEM) and statistical analysis of the results of the fertility 
measurements of BTC transgenic male’s mice. 
Parameter Control L2 L4 
 (n=3) (n=4) (n=5) 
Number of successful matings 3 (100%) 3 (80%) 5 (100%) 
Number of litters/animal 4.3 ± 0.3 3.6 ± 0.3 2.6 ± 0.5 
Interval to the first litter (days) 21.3 ± 0.6 21.0 ± 0.3 31.0 ± 3.6 
Litter size 9.9 ± 0.3 7.9 ± 0.8a 8.0 ± 0.8a
a P < 0.05 
 
 
4.2.2 Females 
 
Successive matings of Btc transgenic female mice with wild-type male mice 
revealed a decrease in litter size compared with litters produced by control mating. 
Control litters had an average size of 9.9 ± 0.3 pups, L2 Btc transgenic females gave 
birth to an average of 5.3 ± 0.7 pups/litter, and L4 Btc transgenic females had an 
average of 4.8 ± 0.5 pups/litter (p<0.001). The interval to the first litter was not 
significantly different between groups (Table 4.3). 
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Table 4.3 Mean values (± SEM) and statistical analysis of the results of the female’s 
fertility study. 
Parameter Control L2 L4 
 (n=3) (n=5) (n=5) 
Number of successful matings 3 (100%) 5 (100%) 4 (80%) 
Number of litters/animal 4.3 ± 0.3 2.8 ± 0.6 2.6 ± 0.5a
Interval to the first litter (days) 21.3 ± 0.6 23.0 ± 1.0 23.4 ± 2.3 
Litter size 9.9 ± 0.3 5.3 ± 0.7 *** 4.8 ± 0.5*** 
a P = 0.0533  
*** P < 0.001  
 
Litter size development showed a significant difference between Btc 
transgenic females and controls females (Figure 4.1).  
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Figure 4.1 Litter size development. A reduction in the mean number of pups per litter in the second 
and third litters as compared to the first litter was observed in Btc transgenic females but not in control 
females (***P < 0.05).  
 
4.3 Evaluation of female puberty onset and estrous cycle tracking 
 
Vaginal opening, the first observable consequence of the rise in circulating E 
that accompanies the onset of puberty in rodents, occurred essentially at the same 
age in transgenic and non-transgenic females (days 24 to 26, data not shown). 
Similarly, the interval between vaginal opening and the first estrus was 
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undistinguishable between both genotypes (data not shown). The interval between 
vaginal opening and the onset of estrous cyclicity, which takes several days in normal 
mice, was slightly increased in the transgenic females, but the difference did not 
reach statistical significance (Figure 4.2A). Figure 4.2B shows the duration of the first 
3 cycles, demonstrating that, although the first cycle was significantly longer in the 
transgenic group, this difference disappeared after the second cycle.  
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Figure 4.2 Evaluation of the onset of estrous cyclicity and cycle length in non-transgenic (wt, n= 3) and 
transgenic animals (tg, n = 4). A) The interval between vaginal opening (VO) and estrous cyclicity 
(defined as the first day of the cycle with duration of 6 or less days) is not different between the 
groups. B) The first estrous cycle has a longer duration in transgenic females. Cyclicity is attained at 
the third cycle in both groups.  
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4.4 Embryo Implantation 
 
In order to evaluate the kinetics of blastocyst attachment, plugged females 
were injected intravenously with a blue dye solution to make the implantation site 
visible (Figure 4.3).  
 
 
Figure 4.3 The attachment reaction. The left uterus is from a wild-type animal at 24:00 h on day 4 with 
the blue bands indicating the implantation sites. The right uterus with no visible blue sites is from a 
BTC transgenic female at the same time after copulation. 
 
The attachment reaction was observed in all of the wild-type mice at 24:00h on 
day 4 of pregnancy and only 13 blastocysts were recovered. In contrast, none of the 
pregnant transgenic mice exhibited blue reaction at this time and many zona-
enclosed and hatched blastocysts were recovered. At 9:00h on day 5 of pregnancy, 
100% of the transgenic females showed attachment reaction and only a few embryos 
were recovered (Table 4.4).  
 
Table 4.4 Initiation of blastocyst attachment reaction in transgenic and age-matched 
wild-type females. Mice without blue sites or blastocysts were not included. 
day genotype  
mice with implantation  
sites (%) 
implantation  
sites (n) 
embryos 
recovered 
4 wt (n=6) 6 (100) 51 13 
4 tg (n=11) 0 (0) 0 53 
5 tg (n=5) 5 (100) 22 8 
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Interestingly, the mean number of total embryos either attached to or 
recovered from the uterus of transgenic females at day 4 (53:11= 4.8) or day 5 (30:5= 
6) was markedly reduced when compared to the number of embryos present in the 
uterus of control females at day 4 (64:6= 10.7). This finding is particularly informative 
since these values correspond quite well to the observed litter sizes in both groups. 
This observation strongly suggests that, although implantation delay is certainly a 
feature of Btc transgenic mice, it does not explain the reduction in the number of 
pups produced. The reason for this reduction must be found in processes taking 
place before implantation (ovulation or fertilization).    
 
4.5 Ovulation and Fertilization analysis 
 
To evaluate whether ovulation or fertilization rates were reduced in transgenic 
animals and could be responsible for the reduction in litter size, we mated transgenic 
and non-transgenic females with vasectomized non-transgenic males. As shown in 
Figure 4.4A, the number of ovulated oocytes obtained did not differ between the two 
genotypes. Next, to evaluate whether fertilization was impaired, we mated females 
from both genotypes to fertile, non-transgenic males and recorded the number of 
fertilized oocytes. While the mean number of ovulated oocytes was again similar in 
both groups, confirming our previous observation (data not shown), we observed a 
statistically significant (P=0.01) reduction in the percentage of fertilized oocytes in 
transgenic (54.7 ± 8.9 %) as compared to control (81.7 ± 5.3 %) females (Figure 
4.4B). The mean number of fertilized oocytes observed in transgenic (41:7 = 5.8 ± 
0.9) and control (119:12 = 9.9 ± 0.5) females is again extremely informative because 
it reflects quite closely the mean litter size observed in these groups. Thus, since no 
significant further embryonic losses will occur after this stage, we have identified 
impaired fertilization as the mechanism responsible for the reduction in the litter size. 
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 and fertilization rates. A) The mean number of ovulated oocytes is not different 
 15) and transgenic (n = 8) animals. B) The proportion of fertilized oocytes is 
 in transgenic females (n = 7) as compared to non-transgenic females (n = 12). 
 maturation 
dy, oocytes were isolated from control (n=11) and Btc transgenic 
and matured in vitro. After in vitro maturation, oocytes were 
 a light microscope, as germinal vesicle (GV, Figure 4.5A), 
Figure 4.5B), or metaphase II (MII, Figure 4.5C).  
ntage of oocytes matured to MII was significantly lower in the 
 as compared to control animals. Conversely, oocytes from 
s showed a higher rate of oocytes at MI, indicating a blockage or 
ration process (Table 4.5).  
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Figure 4.5 Light micrographs of mouse oocytes at the germinal vesicle (A), metaphase I (B), and 
metaphase II (C) stages of nuclear maturation. 
 
 
 
Table 4.5 Analysis of IVM oocytes from Btc transgenic (n=15) and control (n=11) 
mice. Values are the mean ± SEM. Nuclear maturation and the degree of cumulus 
expansion were assessed after 16 hours of culture.  
 
IVM Oocytes 
employed Metaphase I Metaphase II CE Genotype 
n n (%) n (%) (1 to 4) 
control 146 16 (9.8 ± 3) 129 (89.7 ± 3.1) 4 
transgenic 187 36 (19.4 ± 2.8) 150 (80.2 ± 2.6) 4 
P   0.0327 0.0308  
The transgenic and wild-type animals had 1 degenerated oocyte each after IVM. CE 
= cumulus expansion; Metaphase I = neither GV nor polar body; Metaphase II = 1st 
polar body present. 
 
 
4.7  In vitro fertilization 
 
Our analysis of the in vitro fertilization rate, shown as the appearance of two 
pronuclei after 6 h of fertilization, revealed a reduction in the percentage of fertilized 
oocytes of the transgenic animals as compared with control animals. The cleavage 
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rate, evaluated 24 h after the fertilization, was also reduced in oocytes from 
transgenic mice (Table 4.6). Interestingly, in the transgenic group, the number of 
cleaved oocytes was higher than that of oocytes with 2 PN after IVF (82 vs. 75, see 
Table 4.6). This finding supports the idea of delayed oocyte maturation. 
 
Table 4.6 Analysis of IVF of oocytes from Btc transgenic (n=11) and control (n=7) 
mice. Values are the mean ± SEM. The observation of two pronuclei and the 
cleavage to a 2-cell stage were considered an indicative of successful fertilization 
and evaluated 6 and 24 hours after the IVF, respectively. 
 
 
IVF Oocytes 
employed 2 PN Cleavage Genotype 
n n (%) n (%) 
control 87 73 (87.4 ± 4.6) 71 (84.6 ± 5.6) 
transgenic 150 75 (50.6 ± 3.8) 82 (57.5 ± 5.1)  
P   0.0001 0.0034 
2PN = 2 pronuclei present. 
 
4.8 Sperm analysis  
 
Although the fertility of Btc transgenic males appears to be impaired, these 
animals do not display evident alterations in sperm production. Analysis of sperm 
parameters in Btc transgenic males showed no difference compared with non-
transgenic males (Table 4.7).  
 
Table 4.7 Analysis of sperm parameters of Btc transgenic and control mice. 
Genotype Motility (%) Progressivity (%) Concentration (Mio./ml) 
Wt mice 78.3±2.1 (7) 37.1±2.6 (7) 120.3±18.2 (7) 
BTC tg mice 82.0±1.6 (11) 41.0±3.0 (11) 148.3±19.2 (11) 
Values are the mean ± SD, with the number of mice in parentheses. 
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4.9 Immunohistochemical analysis 
 
Using Western blot analyses, we have previously detected increased levels of 
Btc expression in the ovary and uterus of transgenic females as compared to non-
transgenic littermates (data not shown). Since our studies uncovered impaired 
fertilization as the reason behind the reduced litter size, we decided to study the 
expression pattern at the cellular level by employing immunohistochemistry. The 
results confirmed the Western blot analyses, showing increased levels of Btc 
expression in the uterus and ovary (Figure 4.6). Particularly interesting is the high Btc 
expression in granulosa and cumulus cells of the follicles of transgenic females 
(Figure 4.6f). 
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Figure 4.6 Immunohistochemistry of Btc mouse reproductive tract on day 0.5. Note the 
distribution of Btc in uterus and ovary from transgenic mouse (b, f). No
immunostaining was noted when similar sections from wild-typ mice were used (a, c, 
e) 
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5 DISCUSSION 
 
Gene targeting by homologous recombination in embryonic stem cells 
represents a powerful tool for evaluating gene function in whole organisms. Not 
infrequently, the targeted gene encodes a protein belonging to a family of molecules 
sharing structural and functional properties. In this case, gene deletion may be rather 
uninformative because the related proteins can compensate for the loss of the 
targeted proteins (a process called functional compensation). In this case, the 
opposite strategy, that means, increasing the expression levels of the gene of interest 
by means of overexpression may be a much more appropriate approach. This has 
been shown to be true for many families of peptides including the IGF binding 
proteins (Schneider et al. 2000; Wolf et al. 2005). Betacellulin, a member of a family 
of seven Egfr ligands is a further example. Mice lacking Btc develop normally, are 
fertile and display no overt phenotype (Jackson et al. 2003).  Recently, transgenic 
mice overexpressing Btc were generated (Schneider et al. 2005). In addition to 
growth retardation, a variety of pathological alterations including cataract and 
abnormally shaped retinal layers, bone alterations and severe lung alterations, were 
observed. Thus, this model uncovers multiple consequences of Btc overexpression in 
vivo and provides a useful model for examining the effects of Btc excess on different 
organs. In the present study, Btc transgenic mice were employed to study the effects 
of increased growth factor levels in female and male reproduction. The observation of 
relatively ineffective matings involving transgenic females (non-productive matings 
and reduced litter size) during routine breeding led us to functionally evaluate the 
different stages of the reproductive process.  
 
5.1 MALES 
 
Retrospective analysis revealed that matings involving transgenic males were 
often unsuccessful. Systematic fertility measurements revealed that, although the 
mean number of litters produced and the interval to the first litter was unaltered, a 
significant reduction in the number of pups per litter was observed for transgenic 
males as compared to non-transgenic animals. Analyses of sperm parameters 
(concentration, motility, and progressive motility) failed to reveal any difference 
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between transgenic and control age-matched males. Although an impairment of the 
fertilization rate is a probable explanation, an impairment of the early embryonic 
development or blastocyst attachment by increased levels of Btc in the seminal 
plasma of transgenic males cannot be excluded. Thus, the exact cause of the 
reproductive deficit of transgenic males remains to be determined. 
Growth factors of different families have been shown to play a role in male 
reproduction (Bartke et al. 1999; Burns & Matzuk 2002; Cho et al. 2001; Camp et al. 
2005). Particularly interesting are studies showing the effects of depleting circulating 
Egf by sialoadenectomy. After the sialoadenectomy a reduced spermatid count was 
observed and returned to normal with Egf treatment, suggesting a relationship 
between EGF and spermatogenesis (Tsutsumi et al. 1986; Liu et al. 1994). Increased 
testicular Egf concentrations have been shown in synchronized rat testes that were 
closed to the meiotic stages (Bartlett et al. 1990).   
Egf seems to have a physiological role in germ cell development, as 
demonstrated by in vitro stimulation by Egf of spermatogonial proliferation in 
seminiferous tubules of adult rats (Yan et al. 1998; Wahab-Wahlgren et al. 2003). 
The first in vivo evidence that Egf overexpression can adversely affect 
spermatogenesis (hypospermatogenesis) was demonstrated by Wong and 
colleagues (Wong et al. 2000). This report demonstrated that the transgenic male 
mice overexpressing Egf had few post-meiosis II gametes, the animals were sterile 
and had reduced serum testosterone levels. Mice with either single or triple null 
mutations in Egf, Tgfa, and Areg did not show reduced fertility, raising the possibility 
of functional redundancy with Hbegf, Btc, and Ereg (Luetteke et al. 1999).  
This study provides evidence that Btc overexpression does not negatively 
affect spermatogenesis, sperm motility, progression and concentration values.  This 
observation is in agreement with a previous report that mice overexpressing Tgfa did 
not show abnormal testis morphology or spermatogenesis (Mullaney & Skinner 
1992), suggesting that the growth factors may have different roles in 
spermatogenesis. 
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5.2 FEMALES 
 
5.2.1 Fertility Analyses  
 
Despite the extensive research and a lot of information obtained from in vitro 
and in vivo experiments, the precise roles of the Egfr ligands for female and male 
fertility remain largely undefined. As a first step, systematic fertility experiments were 
carried out and confirmed under controlled conditions that the litter size is 
significantly reduced when a transgenic female or male were paired with a control 
animal. Similarly to the effect observed in males, the major reproductive deficit of 
females was the litter size. The interval to the first litter was not altered. Interestingly, 
the litter size development was altered: the size of the second and the third litters 
was reduced as compared with the first litter.  
An effect on litter size has not been reported so far for Btc or other Egfr 
ligands, while this is not an uncommon observation in other growth factor families. 
For instance, female transgenic mice overexpressing IGFBP-6 showed severe 
reproductive defects (Bienvenu et al. 2004). 5–20% of the IGFBP-6 transgenic 
females were sterile and the litter size of fertile transgenic females was small. Litters 
sired by transgenic males were in the normal range. The cause of the reproductive 
deficiency appeared to be an alteration of ovulation and a dramatic decrease in 
plasma LH concentrations, suggesting some hypothalamo-pituitary disorder resulting 
from hIGFBP-6 overexpression in the brain (Bienvenu et al. 2004). 
 
5.2.2 Female Puberty Onset and Estrous Cycle Tracking 
 
 In mammals, puberty begins with a pulsatile release of GnRH, activation of 
hypothalamic neurons secreting LHRH and activation of hypothalamic membrane-
bound growth factor receptors (Ma et al. 1994). An overexpression of Tgfa or a 
central blockade can delay puberty or advance it (Ojeda & Ma 1998; Ojeda et al. 
2003; Junier 2000). Apostolakis and colleagues (Apostolakis et al. 2000) 
demonstrated that Egf, Areg and Tgfa can signal through the ERα and alter rodent 
reproduction. The absence of erbB4 in transgenic mice also delayed sexual 
maturation and a diminished reproductive capacity, related to impaired release of 
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LHRH (Prevot et al. 2003; Prevot et al. 2005).  
Our studies revealed that onset of puberty, evaluated by vaginal opening, was 
not different between Btc transgenic and non-transgenic animals. Furthermore, with 
the exception of a longer first estrous cycle, the transgenic females behaved quite 
similar to control females during the first weeks of puberty. Importantly, starting with 
the third cycle, the mean cycle length in both groups was shorter than 6 days in 
duration, the maximal cycle length considered normal for in different mouse strains 
(Nelson et al. 1990). Since body weight plays (at least partially) a role in triggering 
puberty, the longer first estrous cycles may be related to the fact that transgenic 
females have a lower body weight at the time of puberty as compared to control 
animals (Schneider et al. 2005). Collectively, these results indicate that, with the 
exception of a longer first estrous cycle, onset of puberty is, in essence, not affected 
in transgenic females. 
 
5.2.3 Embryo Implantation 
 
Attachment of the blastocyst to the uterine epithelium initiates the implantation 
process and is followed by locally increased vascular permeability which can be 
visualized in the mouse uterus as distinct blue bands after an intravenous injection of 
a blue dye solution (Reese et al. 2001). Several evidences strongly suggest an 
important role for Egfr in blastocyst attachment. Thus, Tgfa (Tamada et al. 1991); 
(Paria et al. 1994), Hbegf (Das et al. 1994b), Areg (Das et al. 1995) and Ereg and Btc 
(Das et al. 1997a) genes are expressed in the mouse uterus only at sites and time-
points relevant to the implantation process. Interestingly, the Egfr and ErbB4 are 
expressed in blastocysts (Paria et al. 1993a; Paria et al. 1999; Lim et al. 1998). Even 
more convincingly is the report of delayed blastocyst-attachment reaction in 
transgenic mice with timely inappropriate expression of Tgfa in the uterus (Das et al. 
1997b). In this study, delayed implantation was associated with deferred expression 
of Areg, which is probably the most relevant Egfr ligand associated with blastocyst 
implantation. However Tgfa null mice are viable and fertile, showing that a possible 
compensatory mechanism by others Egfr ligands exists. In vitro experiments showing 
that Hbegf can stimulate embryo development and zona hatching provide further 
evidence for a role of this growth factor in the implantation process (Raab et al. 1996; 
Martin et al. 1998). Btc is present in the luminal epithelium and stroma of the mouse 
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uterus (Das et al. 1997a). However, its significance in implantation has not been 
studied so far. 
The reduced fertility of Btc transgenic females could be attributed to one or 
more reproductive dysfunctions, such as a decreased ovulation, fertilization or 
implantation. In light of the abundant experimental data indicating an important role 
for Egfr ligands in this process, we evaluated whether the process of implantation 
was perturbed in these animals. Our studies revealed that delayed blastocyst 
implantation is certainly present in Btc transgenic mice. However, since the total 
number of embryos either attached (visualized as a blue band) or recovered from the 
uterus of transgenic females at day 4 or 5 is almost identical to the observed litter 
size, the reduction in the number of viable embryos did already take place at this 
stage. Consequently, the explanation for the reduced litter size must be disturbed 
ovulation or fertilization rates. Thus, we next evaluated whether these processes 
were negatively affected in transgenic females.  
 
5.2.4 Ovulation and Fertilization Rates in vivo 
 
The implantation process of the Btc transgenic mice was delayed, but this was 
not the explanation for the litter size reduction. For this reason, we decided to 
evaluate the processes taking place before the implantation that is ovulation and 
fertilization. 
Recent studies have implicated selected Egfr ligands (including Btc) as 
paracrine mediators of LH actions in the ovulatory follicle (Hsieh et al. 2005; Conti et 
al. 2006). Specifically, LH stimulated the expression of Areg, Ereg and Btc in mouse 
preovulatory follicles, and these growth factors triggered meiosis and cumulus 
expansion (and the expression of genes associated with this process) in cultured 
follicles in a Egfr-dependent manner (Park et al. 2004; Ashkenazi et al. 2005). 
Recently, prostaglandin synthase 2 and progesterone receptor were identified as key 
molecules involved in this process (Shimada et al. 2006). These findings may help to 
explain the puzzling observation that, in spite of complex actions on the oocyte, 
granulosa and cumulus cells, LH receptor expression is restricted to mural granulosa 
cells (Peng et al. 1991). Importantly, at least for Ereg, the release of the soluble form 
into the follicular fluid by protease-dependent shedding appears to be essential for 
this effect (Ashkenazi et al. 2005). Tgfa and Btc can activate the Erk signaling 
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pathway, which promotes the initialization of the differentiation of granulosa cells 
subsequent to preovulatory follicle selection (Woods & Johnson 2006). Recently, 
Yoshino and colleagues showed that Btc expression is increased by treatment of 
cumulus cells with bone morphogenetic protein 15 (BMP-15), an oocyte-specific 
growth factor that plays a major role in determining ovulation quota in mammals 
(Yoshino et al. 2006). This is an interesting finding because female mice lacking 
BMP-15, although exhibiting no obvious defects in folliculogenesis, produce oocytes 
with a reduced ability to develop into viable embryos (Yan et al. 2001).  
We have evaluated the number of ovulated oocytes and observed that this 
rate did not differ between the transgenic and wild-type animals. However when 
fertilized oocytes were collected, a statistically significant reduction in the percentage 
of fertilized oocytes in transgenic as compared to control females was observed. 
Thus we have identified an impaired fertilization as the reason for the reduction in the 
litter size. 
 
5.2.5 In vitro Maturation and Fertilization 
 
To verify if the fertilization problem was due to an oocyte development 
competence we decided to determine the in vitro maturation rate of the Btc 
transgenic oocytes. Previous investigations showed that Areg, Epi, Hbegf and Btc, 
when added in the culture medium can also recapitulate the oocyte maturation in 
vitro (Richards 1994; Richards et al. 1995; Richards et al. 2002; Park et al. 2004; Pan 
et al. 2004). 
Our studies revealed that the rate of oocytes showing germinal vesicle 
breakdown and reaching metaphase II after in vitro maturation was significantly 
reduced in Btc transgenic females as compared to control littermates. This 
observation can be attributed to a direct or indirect effect of a high expression of Btc 
in the transgenic cumulus cells (as demonstrated by immunohistochemistry). Thus, 
the reduced fertilization observed in Btc transgenic mice could be attributed to a 
maturation defect. Therefore, in vitro fertilization was employed to confirm the 
fertilization ability on the mature oocytes in vitro. 
Our analysis of in vitro fertilization revealed a reduction in the percentage of 
fertilized oocytes of the transgenic animals as compared with control animals. This 
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result makes a negative influence of the oviduct during the fertilization process 
unlikely, uncovering a problem in the cumulus-oocyte complex itself.  
The fact that the maturation of oocytes from transgenic animals is affected to a 
relatively low degree (about 10% less oocytes at MII) makes an impaired maturation 
an improbable explanation for the reduction in litter size (a decrease of about 50%). 
Thus, an impaired fertilization of the mature oocyte is the most likely explanation for 
the fertility defect of Btc transgenic females. 
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6 SUMMARY 
 
Impaired fertility in transgenic mice overexpressing Betacellulin 
 
Peptide growth factors regulate many cellular functions by autocrine, 
paracrine, juxtacrine or endocrine mechanisms. The epidermal growth factor (EGF)-
like peptides are emerging as major players in regulating different aspects of animal 
and human physiology and pathology. The EGF family elicits essential actions in 
reproduction. For instance, different Egfr ligands have been shown to be involved in 
oocyte maturation and ovulation, preimplantational embryonic development, and 
implantation.  
Btc, a member of the Egf family, was initially isolated from a mouse insulinoma 
cell line, and it is expressed in a wide range of tissues in the mouse, with particularly 
high levels in the heart, lung, liver, kidney, pancreas, small intestine, colon, testis, 
ovary and uterus. Btc was identified as one of the Egfr ligands expressed in the 
mouse uterus exclusively at the time of implantation and can also participate as a 
mediator of luteinizing hormone (LH), prostaglandins (PGs) and progesterone 
receptor (PGR).  
Mice lacking Btc are viable, fertile and show no overt phenotype, but 
transgenic mice overexpressing Btc exhibit a whole array of phenotypical alterations. 
In the present study, Btc transgenic mice were employed to study the effects 
of increased growth factor levels in female and male reproduction. The observation of 
relatively ineffective matings involving transgenic females (non-productive matings 
and reduced litter size) during routine breeding led us to functionally evaluate the 
different stages of the reproductive process.  
The reduced fertility of Btc transgenic females could be attributed to one or 
more reproductive dysfunctions, such as a decreased ovulation, fertilization or 
implantation. Therefore, we have studied different aspects of Btc transgenic female’s 
and male’s reproduction, including puberty initiation, ovulation, in vivo and in vitro 
oocyte maturation, sperm parameters, in vivo and in vitro fertilization, and  
implantation in order to uncover the reason for their reduced fertility. 
Successive matings of Btc transgenic males and females mice with wild-type 
mice revealed a decrease in litter size as compared with litters produced by control 
matings. However, the interval to the first litter was not significantly different between 
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groups. Litter size development showed a significant difference between Btc 
transgenic females and controls females. The onset of puberty occurred essentially 
at the same age in transgenic and non-transgenic females. The implantation of the 
Btc transgenic mice was delayed, but this was not the reason for the litter size 
reduction, because the mean number of total embryos either attached or recovered 
from the uterus of transgenic females was already markedly reduced when compared 
to the number of embryos present in the uterus of control females. For this reason, 
the explanation must be found in processes taking place before implantation 
(ovulation or fertilization). We evaluated the number of ovulated oocytes and 
observed that this parameter did not differ between the two genotypes, however, we 
observed a statistically significant reduction in the percentage of fertilized oocytes in 
transgenic as compared to control females, identifying the reason for the reduction in 
the litter size. Next, we carried out in vitro maturation of oocytes. The timing of 
nuclear maturation differed between transgenic and control oocytes. Therefore, we 
decided to evaluate the in vitro fertilization rate, which turned out to be impaired in 
the transgenic group. The expression pattern at the cellular level, studied by 
immunohistochemistry, revealed a high expression of Btc in the transgenic cumulus 
cells, which could be an explanation for the altered in vivo and in vitro fertilization. 
Although the fertility of Btc transgenic males appears to be impaired, these 
animals do not display evident alterations in sperm production. This study provides 
evidence that Btc overexpression does not negatively affect spermatogenesis, sperm 
motility, progression and concentration values. 
Future studies are needed to clarify whether the altered fertilization is in fact 
caused by the high expression of Btc in the transgenic cumulus cells. Furthermore, 
experiments involving the overexpression of a non-sheddable form of Btc are 
underway and will help to clarify the actions of precursor (membrane-bound) versus 
mature Egfr ligands during oocyte maturation and fertilization. 
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7 ZUSAMMENFASSUNG 
 
Fruchtbarkeitsstörungen bei transgenen Mäusen, die Betacellulin 
überexprimieren 
 
 Wachstumsfaktoren regulieren viele zelluläre Funktionen durch 
autokrine, parakrine, juxtakrine oder endokrine Mechanismen. Bei Mensch und Tier 
spielen die EGF- (epidermale Wachstumsfaktoren) ähnliche Peptide eine 
übergeordnete Rolle, weil sie in den unterschiedlichsten Bereichen von Physiologie 
und Pathologie Einfluss nehmen können. In der Fortpflanzung werden durch die 
EGF-Familie essentielle Mechanismen ausgelöst. Es konnte zum Beispiel gezeigt 
werden, dass unterschiedliche Egfr Liganden für die Oozytenentwicklung, deren 
Ovulation, in die präimplantative embryonale Entwicklung, und in die Implantation 
von Bedeutung sind.  
Btc, ein Mitglied der Egf Familie, wurde erstmals bei einer 
Mäuseinsulinomzelllinie beschrieben. Eine Btc-Expression kann in vielen Geweben 
der Maus nachgewiesen werden und weist ein besonders hohes Niveau im Herzen, 
in der Lunge, in der Leber, in der Niere, im Pankreas, im Dünndarm, im Dickdarm, im 
Hoden, im Eierstock und in der Gebärmutter auf. Es wurde festgestellt, dass Btc 
einer der Egfr Liganden ist, die in der Gebärmutter der Maus ausschließlich zur Zeit 
der Implantation exprimiert werden. Außerdem kann es als Mediatoren des 
luteinisierenden Hormons (LH), der Prostaglandine (PGs) und des Progesteron 
Rezeptors (PGR) fungieren. 
 Btc-knock-out Mäuse sind lebensfähig, fruchtbar und zeigen keinen 
offensichtlichen Phänotyp. Transgene Mäuse, die Btc überexprimieren, haben jedoch 
eine Reihe von phänotypischen Veränderungen. 
In der vorliegenden Untersuchung wurden Btc-transgene Mäuse eingesetzt, 
um die Effekte eines erhöhten Spiegels dieses Wachstumfaktors in der weiblichen 
und männlichen Fortpflanzung zu studieren. Die Beobachtung, dass die Anpaarung 
von transgenen Weibchen im Rahmen der Routinezucht oft erfolglos (keine 
Trächtigkeiten oder verringerte Wurfgröße) war, veranlasste uns dazu die 
unterschiedlichen Stadien der Fortpflanzung funktionell auszuwerten. 
Die verringerte Fruchtbarkeit der Btc-transgenen Weibchen kann mit einer 
oder mehreren reproduktiven Funktionsstörungen wie einer verringerten Ovulation, 
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Befruchtung und/oder Implantation zusammenhängen. Deswegen haben wir die 
unterschiedlichen Phasen in der weiblichen und männlichen Fortpflanzung der Btc-
Mäuse untersucht. Um den Grund für ihre verringerte Fruchtbarkeit aufzudecken, 
wurde der Anfang der Pubertät, die Ovulation, die in vivo und in vitro Oozytenreifung, 
Spermienzellenparameter, die in vivo und in vitro Befruchtung und die Implantation 
untersucht. 
Im Rahmen von aufeinanderfolgenden Anpaarungen (Daueranpaarungen) von 
Btc-transgenen Männchen und Weibchen mit Wildtyp-Mäusen konnte eine 
Reduzierung der Wurfgröße im Vergleich zu Würfen von Wildtyp-Anpaarungen 
errechnet werden. Die Intervalle zwischen Anpaarung und erstem Wurf unterschiede 
sich in den Gruppen nur unerheblich. Die Wurfgrößenentwicklungen im Laufe der 
Daueranpaarung von Btc-transgenen Weibchen zeigten jedoch erhebliche 
Unterschiede im Vergleich zu der von Wildtyp-Weibchen auf. Der Anfang der 
Pubertät trat im Wesentlichen im gleichen Alter bei transgenen und Wildtyp-
Weibchen auf. Die Implantation in Btc-transgenen Mäusen war verzögert, das war 
allerdings nicht der Grund für die kleineren Wurfgrößen, da die Anzahl der 
implantierten oder aus der Gebärmutter gespülten Embryonen von transgenen 
Weibchen im Vergleich mit der Zahl der Embryonen aus wild-typ Weibchen bereits 
deutlich reduziert war. Somit musste die Erklärung für die verringerte Fruchtbarkeit in 
der Zeit vor der Implantation (Ovulation oder Befruchtung) gesucht werden. Wir 
werteten die Anzahl der ovulierten Oozyten (Ovulationsrate) aus und konnten hierbei 
keinen Unterschied zwischen den Genotypen feststellen. Da wir jedoch eine 
statistisch signifikante Reduktion des Anteils an befruchtetet Oozyten in transgenen, 
verglichen mit wild-typen Mäusen, beobachteten konnten, war damit eine mögliche 
Erklärung für die geringere Fruchtbarkeit und die verminderte Wurfgröße gefunden. 
Mittels in vitro Maturation konnte gezeigt werden, dass der Anteil an Oozyten im 
Meiose II Stadium in der transgenen Gruppe signifikant reduziert war. Die 
Auswertung der Befruchtungsrate nach in vitro Fertilization zeigte, dass auch dieser 
Parameter bei den transgenen Weibchen signifikant reduziert war. Das 
Expressionsmuster auf zellulärer Ebene, untersucht mittels Immunhistochemie, 
ergab eine hohe Expression von Btc in den transgenen Cumuluszellen. Dies könnte 
eine Erklärung für die gestörte in vivo und in vitro Befruchtung sein. 
Diese Studie zeigt, dass eine Btc-Überexpression die Spermatogenese, 
Spermienzellenmotilität, progressive Motilität und die Konzentration der Spermien 
 52
nicht negativ beeinflusst.  
Zukünftige Studien müssen mögliche Zusammenhänge zwischen der hohen 
Expression von Btc in transgenen Cumuluszellen und der veränderten 
Befruchtungsfähigkeit abklären. Außerdem sind Experimente, die die Überexpression 
einer „non-sheddable“ (nicht abspaltbar) Form von Btc berücksichtigen in Planung. 
Diese werden helfen, die Wirkung des membrangebundenen Precursorproteins im 
Vergleich zu reifen Egfr Liganden während der Oozytenreifung und der Befruchtung 
zu erklären. 
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